A Pharmacokinetic Study to Assess Nevirapine [Viramune] Levels in HIV Infected Patients With Impaired Hepatic Functions

ClinicalTrials.gov ID: NCT00144248

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT00144248. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 12, 2026, 9:57 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Pharmacokinetic Study to Assess Nevirapine Levels in HIV-infected Patients With Impaired Hepatic Function

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The objective of this study was to evaluate the steady-state clearance of nevirapine among HIV-1 positive patients with hepatic fibrosis, and to examine whether the degree of hepatic impairment influences clearance.

Study identification

NCT ID: NCT00144248
Recruitment status: Completed
Study type: Interventional
Phase: Phase 4
Lead sponsor: Boehringer Ingelheim; Industry
Enrollment: 51 participants

Conditions and interventions

Conditions

Interventions

nevirapine Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Jun 25, 2004 (Actual)
Primary completion: Jun 1, 2006 (Actual)
Completion: Not listed
Last update posted: Dec 1, 2023

Started 2004

United States locations

U.S. sites: 5
U.S. states: 3
U.S. cities: 4

Facility	City	State	ZIP	Site status
Boehringer Ingelheim Investigational Site	Bakersfield	California	—	—
Boehringer Ingelheim Investigational Site	San Francisco	California	—	—
California Pacific Medical Center	San Francisco	California	—	—
Albany Medical College, MC 142	Albany	New York	—	—
Boehringer Ingelheim Investigational Site	Providence	Rhode Island	—	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 3 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT00144248, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Dec 1, 2023 · Synced Nov 12, 2026